Australia's largest stock trading and investment forum Australia's #1 stock forum

BDC

0.00%

52.0¢ bardoc gold limited

What magnesium asset?

First 196 Last

Share
Profile

Follow
AisforApple

469 Posts.

86

30/09/21

16:32

Post #: 56473372
Share

Originally posted by CYMON: ↑

I think that would be the plan. My guess is that it will either the Paddington Mine owner (Norton) and / or NST. The refractory ore would go to NST whilst Norton could look at one of the other deposits that would suit their mill. As we are not limited by the through put of our own mill, there is no reason why the team could not run simultaneous operations with different parties across the other assets. In this case, a partnership model would suit the several large deposits we have. We could utilise both man power and equipment already held by a bigger producer.

Having said that though, it is also very possible to see a party offer to take over all gold operations. Assuming that the price offered is substantial we could see the company divest of the gold assets, issue a special dividend to all shareholders, leaving the company as a shell with the magnesium asset as well as a portion of the funds to perhaps acquire other "green metal" potential.

Thinking about this further, i think this is actually very positive for BDC. We remove the substantial dilution that would have come with the funds required for the build, skip the commissioning and associated risks whilst allowing simultaneous monetisation across several assets. I'm starting to see this a big advantage for the group.

Expand

What magnesium asset?

BDC Price at posting: 4.6¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Good habits matters when it comes to finances

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN